![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Similar Efficacy and Safety By Subgroup in DRIVE-AHEAD: DOR/3TC/TDF vs EFV/FTC/TDF
|
|
|
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
Chloe Orkin1; Kathleen E. Squires2,8; Jean-Michel Molina3; Paul E. Sax4; Wing-Wai Wong5; Otto Sussmann6; Richard Kaplan7; Anthony Rodgers8; Xia Xu8; Gina Lin8; Sushma Kumar8; George J. Hanna8; Carey Hwang8; Elizabeth Martin8 for the DRIVE-AHEAD Study Group
1Royal London Hospital, London, UK; 2Thomas Jefferson University, Philadelphia, PA, USA; 3Universite Paris Diderot, Hôpital Saint-Louis, Paris, France; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 5Taipei Veterans General Hospital, Taipei, Taiwan; 6Asistencia Cientifica de Alta Complejidad SAS, Bogotá, Colombia; 7Desmond Tutu HIV Foundation, Cape Town, South Africa; 8Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA
![0306181](../images%20/030618/030618-6/0306181.gif)
![0306182](../images%20/030618/030618-6/0306182.gif)
![0306183](../images%20/030618/030618-6/0306183.gif)
![0306184](../images%20/030618/030618-6/0306184.gif)
![0306185](../images%20/030618/030618-6/0306185.gif)
![0306186](../images%20/030618/030618-6/0306186.gif)
![0306187](../images%20/030618/030618-6/0306187.gif)
![0306188](../images%20/030618/030618-6/0306188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|